chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Tested positive for COVID-19 by Rapid 6/26/21, even though she was vaccinated,  Pfizer 1st dose 12/20/2020  Pfizer 2nd dose 1/08/2021  Experienced the following symptoms post-vaccination Nausea ,Headaches ,Tender arm were shot. Symptoms of the vaccine lasted two days.
Pt was administered the vaccine on 10/21/2020 Wed, 10/24/2020 Sat. pt had itching all over body, 10/25/2020 Sunday pt experienced an itchy rash all over body.   Mother administered bendaryl twice every 4 hours for resolution
Information has been received concerning a case in litigation regarding female pt who on approximately 3/23/00 was vaccinated, at the age of 5 months, with her second dose of hep B vaccine (lot not provided), the first and third doses of hep B vaccine (manuf unk) were given on or aout 2/2/00 and 11/8/00 (lot not provided). Other vaccinations included four doses of Tetramune given on or about 2/2/00, 6/12/00 and 12/13/00 (lot not provided); and three doses of HIBTITER given on or about 2/2/00, 6/12/00 and 12/13/00 (lot not provided). It is alleged that the cumulative effects of the pt's infant injections containing the mercury laden preservative, thimerasol, are the toxic neurological effects of mercury poisoning. As a result of mercury in thimerosal-adulterated infant injections, the pt suffers and in the future will continue to suffer from the toxic neurological effects of mercury poisoning. Upon internal review, the toxic neurological effects of mercury poisoning were considered to be other important medical events (OMIC). Additional info is expected.
My right arm is painful. My fingers were cold & numb, & I could hardly touch anything to where I could feel it, or lift anything.; I thought I was going to die; Every muscle in my body hurt; This spontaneous case was reported by an other health care professional and describes the occurrence of PAIN IN EXTREMITY (My right arm is painful.), HYPOAESTHESIA (My fingers were cold & numb, & I could hardly touch anything to where I could feel it, or lift anything.), FEELING ABNORMAL (I thought I was going to die) and MYALGIA (Every muscle in my body hurt) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 065F21A and 011J20A) for COVID-19 vaccination. No Medical History information was reported.On 20-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form.On 20-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form.On 21-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 21-Nov-2021, the patient experienced HYPOAESTHESIA (My fingers were cold & numb, & I could hardly touch anything to where I could feel it, or lift anything.), FEELING ABNORMAL (I thought I was going to die) and MYALGIA (Every muscle in my body hurt). On 22-Nov-2021, the patient experienced PAIN IN EXTREMITY (My right arm is painful.). At the time of the report, PAIN IN EXTREMITY (My right arm is painful.) had not resolved and HYPOAESTHESIA (My fingers were cold & numb, & I could hardly touch anything to where I could feel it, or lift anything.), FEELING ABNORMAL (I thought I was going to die) and MYALGIA (Every muscle in my body hurt) outcome was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.No relevant concomitant medications were reported. No treatment information was provided.
When I received the COVID booster I would have been approximately 4 weeks pregnant.  I had a positive pregnancy test 6 days after receiving the COVID booster.  I started bleeding 8 days after receiving the COVID booster.   I had another positive pregnancy test, at the advice of one of my doctor's offices.  At a follow up 3.5 weeks after the bleeding, my doctor confirmed I had miscarried.   I have one child and no history of miscarriages.
had additional small raised dots covering a 4 inch diameter circle around the injection site.; the injection site was warm; swollen like an egg; it hurting; This spontaneous report was received from a consumer concerning her daughter, a 9.5-year-old female patient. No concurrent condition, medical history, or concomitant therapy was reported.  On 14-AUG-2021 (Saturday), the patient was vaccinated with the first dose of quadrivalent human papillomavirus (types 6,11,16,18) recomb. Vaccine (GARDASIL) (strength, dose, route, lot# and expiration date unknown) for prophylaxis.         On 16-AUG-2021 (Monday), the injection site was warm to the touch (vaccination site warmth), swollen like an egg (vaccination site swelling) and had additional small raised dots covering a 4 inch diameter circle around the injection site (vaccination site mass). She also complained of it hurting (vaccination site pain). The patient was not recovered from all events. The causality assessment was not provided.
Patient fainted approximately three minutes after his vaccination. He regained consciousness immediately and we moved him to the floor with his feet elevated. We asked him a series of questions to assess his health. He was pale and sweaty but his blood pressure and pulse were stable. We monitored him for roughly 20 minutes after the incident while continuously checking his pulse and blood pressure. He denied any further intervention/assistance and insisted that he felt fine. He left on his own accord.
BODY ACHES; MUSCLE ACHES; LOWER BACK PAIN; HEADACHE. TOOK TYLENOL
Left ring finger pressure sensation, immediately after injection & lasting >15 minutes after injection. Patient attempted to stretch the area move fingers. No improvement. Routed to Urgent Care for follow up. No new or worsening sx during monitoring.
Information has been received from a registered nurse concerning a 4 year old boy who on 01-MAY-2008 was vaccinated with the first dose of OKA/MERCK injection. On 10-OCT-2006 the patient received ENDERS-EDMONSTON, JERYL LYN, WISTAR RA 27/3, OKA/MERCK upgrade process, MSD for second dose. On 15-MAY-2008 the patient came to physician's office with a temperature 100'F and the patient had developed spots under his arms and on his body and they think that it is chicken pox, but not definite yet because they ran some tests but are still waiting for the test results to confirm it. Per nurse, the patient's spots were itchy. The patient's adverse events persisted. Additional information has been requested.
After the booster shot, I had muscle soreness and that barley lasted a day. It was mild this was in the first 72 hours. I went to the emergency room on October 19, 2021 due to a bad migraine that I am still suffering with.
Patient first reported loss of vision (everything turning dark) followed by loss of hearing. Then began to sweat and lose color. She was nodding off and losing consciousness. When she would open her eyes she was not looking at me and was not responding to any questions like she couldn't see or hear me. After 5-10 minutes we got her lying in the floor with her feet up in a chair and she regained consciousness. Ultimately, we feel it was a vasovagal response.
slight soreness; This is a spontaneous report from a contactable healthcare professional (patient). This 24-year-old male patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; lot number EL3249) intramuscularly in the right arm on 19Jan2021 at 19:00 (at the age of 24-years-old) as a single dose for COVID-19 immunization. Medical history and concomitant medications were not reported. Prior to vaccination, the patient was diagnosed with COVID-19. The patient had no known allergies. The patient previously received the first dose of BNT162B2 (lot number EK9231) intramuscularly in the right arm on 29Dec2020 at 18:45. On 20Jan2021 the patient experienced slight soreness. No treatment was provided for the event. The clinical outcome of slight soreness was recovered on an unspecified date. It was also reported the patient was not tested for COVID-19 post vaccination.
Myalgia, Arthralgia, Fever, chills, site pain Narrative: : Sore arm, Body/joint aches, Mild chills, Mild fever (? all clear by Jan 14 12noon)
Inappropriate schedule of vaccine; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a female patient who received HAB (Twinrix) for prophylaxis.   Previously administered products included Twinrix (1st dose received in March 2023).   In JUN-2023, the patient received the 2nd dose of Twinrix. In JUN-2023, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Inappropriate schedule of vaccine). The outcome of the drug dose administration interval too long was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date: 09-JUN-2023 Exact date of vaccinations were unknown. Lot and expiration of vaccinations were unknown. The reporter consented to follow up. The patient received 2nd dose of Twinrix, later than the recommended interval, which led to lengthening of vaccination schedule.
Headache; fatigue; rash on palm of hands (bilateral, began the day after the vaccine, not other place on body other than all fingers); This is a spontaneous report from a contactable other healthcare professional (patient). A 48-year-old female patient (not pregnant) received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number: E3247), intramuscular on 23Jan2021 09:15 at single dose in left arm for COVID-19 immunisation. No other vaccine was given within 4 weeks prior to the COVID vaccine. The patient was vaccinated at hospital. Patient age at time of vaccination was 48 years. Medical history included asthma, seasonal allergies, scoliosis, and allergy to Sulfa. Concomitant medications included sertraline hydrochloride (ZOLOFT), cetirizine hydrochloride (ZYRTEC), montelukast (MONTELUKAST), fluticasone (FLUTICASONE), fluticasone propionate, salmeterol xinafoate (ADVAIR), bifidobacterium lactis (PROBIOTIC) and multivitamin. On 24Jan2021 at 12:00 AM the patient experienced headache, fatigue, rash on palm of hands (bilateral, began the day after the vaccine, not other place on body other than all fingers). The events resulted in doctor or other healthcare professional office/clinic visit. The patient was prescribed prednisone and topical hydrocortisone for the events. The events were resolving. Prior to vaccination, the patient was not diagnosed with COVID-19 and since the vaccination, has not been tested for COVID-19.
Face was drooping; Loss of taste; A spontaneous report was received from a physician concerning, a 58-year-old, male  patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced loss of taste/ageusia and face drooping/facial paralysis.   The patient's medical history included COVID-19 approximately six months prior to this event. Concomitant product use was not provided by the reporter.  On 09 Jan 2021, approximately 3 days prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (Lot number: unknown) intramuscularly for prophylaxis of COVID-19 infection.   On 11 Jan 2021, after receiving mRNA-1273, the patient experienced loss of taste buds. On 20 Jan 2021 patient noticed that his face "felt funny" while drinking water and went to the mirror where he saw the right side of his face was drooping. Patient was seen by PCP on 25 Jan 2021.  Treatment for the events included high dose steroid therapy and valacyclovir 1 gm by mouth twice daily for ten days.  Action taken with mRNA-1273 in response to the events was unknown.   The outcome of the events, ageusia and face dropping, were considered unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. Further information has been requested.
This case was reported by a physician via market research programs and described the occurrence of SLE flare in a adult patient who received Herpes zoster (Shingles vaccine unknown) for prophylaxis. Concurrent medical conditions included systemic lupus erythematosus. On an unknown date, the patient received Shingles vaccine unknown. On an unknown date, less than a year after receiving Shingles vaccine unknown, the patient experienced SLE flare (serious criteria GSK medically significant) and fever. On an unknown date, the outcome of the SLE flare and fever were unknown. The reporter considered the SLE flare and fever to be possibly related to Shingles vaccine unknown. Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but was selected as adult as per vaccine indication. The reporter's SLE patient who had real but short-lived events that, the reporter interpreted as lupus flares, with fever. This case has been linked to the cases US2018GSK182344, US2018GSK183955, US2018GSK183956, US2018GSK183957 and US2018GSK183959, reported by same reporter.
Initial unsolicited report received from a consumer (patient's mother via social media) on 13 October 2015. This case is linked to 2015SA162207, 2015SA162201 (same reporter, different patients). This case involves a male patient (age not reported) who was vaccinated with a dose of DTaP (batch number, expiration date, dose, dose number, route and site of administration were not reported) on an unspecified date. The patient's medical history and concomitant medication were not reported. On an unspecified date following the vaccination, the patient developed a Tourette like effect with uncontrollable facial tics and rapid blinking. It was reported that the patient's healthy son was forced to undergo a DPT vaccine and he then developed events. Laboratory investigation and corrective treatment were not reported. The outcome of the events was not reported. Upon internal review, company assessed the event of Tourette like effect as serious and important medical event. List of documents held by sender: none.
pt recv vax 25SEP96 & 7JUL97 pt exp breakthrough vax disease consisting of vesicles & papules;
To, The  Centers for Disease Control and Prevention The patients. I am a 27-year-old female residing since August 2019. I am a Resident and an immigrant. On the 20th of April, 2021 I took my first shot of the Pfizer-BioNTech COVID-19 vaccine in city where I reside. After 48 hours of taking the vaccine, I started experiencing extreme fatigue, dehydration, and chills. I also registered a fever of close to 101 on a few nights in the week after. I thought this was a temporary side-effect of the vaccine, but the side-effects persisted and was not dying down. Over the next 2-3 weeks my health condition waxed and waned. I was facing extreme fatigue to the extent it had disrupted my normal life, heavy dehydration, loss of appetite, feeling cold easily, especially in the evenings. I called up the center and asked if I could delay my 2nd COVID-19 Pfizer shot, but because it is generally advised to take the second shot within a 28-day period, I decided to go ahead and take my second shot on May 14th. I took a couple of Acetaminophen tablets this time to help reduce a possible fever. Over the next weeks, my condition did not seem to change, even though I was done with both my shots. I continued to face fatigue and weakness, I had lost 10-11 pounds, a huge loss in appetite, I started noticing heavy hairfall daily. My period had not come since taking the vaccine. In the early month of June, I noticed dark red blotchy marks that had appeared on both my arms. My health started deteriorating heavily in June, there were days when I could sleep all day. I started noticing a fever which climbed to 101-102 daily, especially in the evenings and continuous shivering. Seeing the signs of a serious medical condition, I filed for emergency leave from my workplace and decided to fly back to where my family resides. I landed in the 30th of June, 2021. I was admitted to a hospital in the Emergency Unit on the very same day and where I continued to remain hospitalized until the 9th of July. I was hospitalized for a period of 10 days, during which multiple blood tests, scans and procedures were run on me, at the end of which I was diagnosed with now having a chronic illness, an Autoimmune disorder called Systemic Lupus Erythematosus. I am currently, recouping from my illness and undergoing treatment for SLE. I do not know if there was a correlation between my taking this vaccine and the triggering of my illness, but if there is a possibility of the vaccine triggering an Autoimmune disorder in healthy individuals, I would like the concerned authorities to make a note of it. Symptoms: Extreme Fatigue, Continuous High Fever, Heavy Hairfall, Loss of Appetite, Feelings of Nausea, Red marks on arms, Weight Loss, No menstruation
Sprained ankle/Sprained right ankle; 01 Feb 2021, patient received 1st dose COVID-19 Vaccine and on 1-Apr 2021, patient received 2nd dose COVID-19 Vaccine; This spontaneous case was reported by a consumer and describes the occurrence of LIGAMENT SPRAIN (Sprained ankle/Sprained right ankle) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (01 Feb 2021, patient received 1st dose COVID-19 Vaccine and on 1-Apr 2021, patient received 2nd dose COVID-19 Vaccine) in a 64-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for Rheumatoid arthritis.    Concomitant products included COVID-19 VACCINE for COVID-19 vaccination, HYDROXYCHLOROQUINE for an unknown indication.   On 01-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) 40 milligram. On 01-Apr-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (01 Feb 2021, patient received 1st dose COVID-19 Vaccine and on 1-Apr 2021, patient received 2nd dose COVID-19 Vaccine). On an unknown date, the patient experienced LIGAMENT SPRAIN (Sprained ankle/Sprained right ankle). At the time of the report, LIGAMENT SPRAIN (Sprained ankle/Sprained right ankle) was resolving and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (01 Feb 2021, patient received 1st dose COVID-19 Vaccine and on 1-Apr 2021, patient received 2nd dose COVID-19 Vaccine) outcome was unknown.            No Medical History information was reported.  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. The reporter's causality for the event of ligament sprain was no reasonable possibility with HUMIRA(ADALIMUMAB).  No treatment medications were reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Sore arm, swelling, inflammation, chills, fatigue, interrupted sleep x 2 days.  Took Ibuprofen x 3 and Tylenol x 2.
patient have taken flu shots only 5 times & developed flu symptoms afterwards; Initial information received on 17-Nov-2020 regarding an unsolicited valid non-serious social media case received from a consumer.  This case involves a unknown demographics patient who developed flu symptoms (influenza), while he/she received vaccine INFLUENZA VACCINE.  The patient's medical history, medical treatment(s), vaccination(s) and family history were not provided.   Concomitant medications were unknown.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number not reported via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed flu symptoms (influenza), (Unknown latency) following the administration of INFLUENZA VACCINE.  Final diagnosis was patient was influenza.   Relevant laboratory data was not reported.  It was not reported if the patient received a corrective treatment.  The event outcome was reported as Unknown.  There will be no information available on the batch number for this case.
Fever; Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever) and FATIGUE (Fatigue) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in May 2020.   On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PYREXIA (Fever) and FATIGUE (Fatigue). At the time of the report, PYREXIA (Fever) and FATIGUE (Fatigue) outcome was unknown.            Concomitant medications not reported.  No treatment information was provided.   This case was linked to MOD-2021-031118 (Patient Link).
p/vax pt devel diffuse rash w/wheezing; erythema multiforme; rash; swelling joints
vaccine was administered and some of the vaccine leaked out; vaccine was administered and some of the vaccine leaked out; This spontaneous case was reported by a pharmacist and describes the occurrence of UNDERDOSE (vaccine was administered and some of the vaccine leaked out) and DEVICE CONNECTION ISSUE (vaccine was administered and some of the vaccine leaked out) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Mar-2021, the patient experienced UNDERDOSE (vaccine was administered and some of the vaccine leaked out) and DEVICE CONNECTION ISSUE (vaccine was administered and some of the vaccine leaked out). At the time of the report, UNDERDOSE (vaccine was administered and some of the vaccine leaked out) outcome was unknown and DEVICE CONNECTION ISSUE (vaccine was administered and some of the vaccine leaked out) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Most recent FOLLOW-UP information incorporated above includes: On 05-Mar-2021: No specific follow-up information recorded. On 06-Apr-2021: NNI; Sender's Comments: This report refers to a case of Vaccine Underdose and Syringe Connection Issue for mRNA-1273, lot # 029A21A
Itchy Throat 10:20 25mg Benadryl PO given 10:30 no longer itchy throat
Initial report receive from a healthcare professional on 19 October 2012. A patient, whose age, gender, medical history and concomitant medications were not reported, had received FLUZONE (Lot number UH746AA, route and anatomical site of vaccination was not reported) on an unspecified date. The patient had gastrointestinal symptoms, low grade fever, body aches and dizziness following vaccination. Laboratory details and corrective treatment was not reported. The patient's outcome was unknown. List of documents held by the sender: None.
24 hrs. after immunized developed headache, nausea, T 102 & vomited 2-3 times (8-17 afternoon late). 8/18 Awoke with T 102. Fever decreased with MOTRIN. 8/18 pt. noticed improved by 1:30pm 8-18-11.
Redness and pain in the site of injection. Lymph nodes swelling, heat, and pain: under armpit, shoulder, and neck. All on the left side. Low grade fever, malaise.
3rd pt of 3 devel welts & itching @ the site of inj p/vax;
I had headache, server coughing, fatigue, lost of apatite. I had a fever of 102. I went to see the doctor. He sent me to get antibodies. I did a COVID-19 test, positive.
Modern a COVID-19 vaccine EUA arm swelled and rash at injection site 2 weeks after injection